EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Is APOE--epsilon4 a risk factor for cognitive impairment in normal aging?



Is APOE--epsilon4 a risk factor for cognitive impairment in normal aging?



Neurology 54(11): 2082-2088



Objectives: To examine the relationship between APOE genotype and cognitive functioning in normal aging, and to determine whether this relationship was moderated by age or the presence of a number of disease conditions, including cardiovascular disease and diabetes. Methods: The sample was drawn from the Charlotte County Healthy Aging Study, a community-based, cross-sectional study of randomly selected older adults in Charlotte County, FL. A total of 413 older adults (mean age = 72.90 years) were examined in the current study. Participants completed tasks that indexed a variety of dimensions of cognitive functioning, including episodic memory, implicit memory, psychomotor speed, and attention. In addition, participants provided self-reported and objective indices of health status and were genotyped for APOE. Results: Mean-level results indicated that groups with and without the APOE-epsilon4 allele performed similarly on all domains of cognitive functioning. Significant age group differences were observed in episodic memory, psychomotor speed, and attention but not implicit memory. Significant gender differences were present for episodic memory and the Stroop test. Analyses also indicated that participants' age did not exert an impact on the relationship between APOE-epsilon4 and cognitive functioning. Further, the presence of cardiovascular disease or diabetes did little to moderate the relationship between APOE-epsilon4 and cognition. Conclusions: The authors found no evidence for a relationship between presence of the APOE-epsilon4 allele and cognitive functioning. Further, age or the presence of a number of chronic conditions did not significantly moderate the effect of APOE genotype on cognitive performance. These results indicate that the presence of the epsilon4 allele is not a risk factor for cognitive impairment in normal aging.

(PDF emailed within 1 workday: $29.90)

Accession: 010885932

Download citation: RISBibTeXText

PMID: 10851367



Related references

Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dementia and Geriatric Cognitive Disorders 27(5): 458-464, 2009

APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment. Neurology 63(8): 1399-1402, 2004

Association between ApoE epsilon4 and cognitive impairment after stroke. Dementia and Geriatric Cognitive Disorders 27(6): 525-533, 2009

APOE epsilon4 allele is associated with cognitive impairment in patients with multiple sclerosis. Neurology 71(15): 1203; Author Reply 1203-1203; Author Reply 1203, 2008

APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis. Multiple Sclerosis 15(12): 1489-1494, 2010

Cognitive impairment and the role of the ApoE epsilon4-allele after stroke--a 13 months follow-up study. International Journal of Geriatric Psychiatry 25(8): 833-842, 2011

APOE epsilon4 allele carriers: Biological, psychological, and social variables associated with cognitive impairment. Aging & Mental Health 14(6): 679-691, 2011

The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. Neuroepidemiology 34(1): 43-49, 2010

The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology 60(7): 1077-1081, 2003

The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease. Plos One 11(7): E0157514-E0157514, 2016

Regional cerebral perfusion in patients with Alzheimer's disease and mild cognitive impairment: effect of APOE epsilon4 allele. Neuroradiology 55(1): 25-34, 2013

APOE and COMT polymorphisms are complementary biomarkers of status, stability, and transitions in normal aging and early mild cognitive impairment. Frontiers in Aging Neuroscience 6(): 236-236, 2014

APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Archives of Neurology 67(1): 93-98, 2010

Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. Cmaj 171(8): 863-867, 2004

APOE-epsilon4, depressive symptoms, and cognitive decline in Chinese older adults: Singapore Longitudinal Aging Studies. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 64(2): 306-311, 2009